Page last updated: 2024-08-26

artenimol and Bone Loss, Osteoclastic

artenimol has been researched along with Bone Loss, Osteoclastic in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Ding, D; Feng, G; Jin, Q; Ma, L; Yan, J; Zhou, Y	1

Other Studies

1 other study(ies) available for artenimol and Bone Loss, Osteoclastic

Article	Year
Dihydroartemisinin attenuates osteoclast formation and bone resorption via inhibiting the NF‑κB, MAPK and NFATc1 signaling pathways and alleviates osteoarthritis. International journal of molecular medicine, 2022, Volume: 49, Issue:1 Topics: Actins; Animals; Artemisinins; Bone Marrow Cells; Bone Resorption; Cartilage, Articular; Cell Differentiation; Male; MAP Kinase Signaling System; Mice; NF-kappa B; Osteoarthritis; Osteoclasts; Osteogenesis; Rats, Sprague-Dawley; RAW 264.7 Cells; Transcription Factors	2022

Article

Year

Dihydroartemisinin attenuates osteoclast formation and bone resorption via inhibiting the NF‑κB, MAPK and NFATc1 signaling pathways and alleviates osteoarthritis.

International journal of molecular medicine, 2022, Volume: 49, Issue:1

Topics: Actins; Animals; Artemisinins; Bone Marrow Cells; Bone Resorption; Cartilage, Articular; Cell Differentiation; Male; MAP Kinase Signaling System; Mice; NF-kappa B; Osteoarthritis; Osteoclasts; Osteogenesis; Rats, Sprague-Dawley; RAW 264.7 Cells; Transcription Factors

2022